$ALAB

Dyckerhoff Stefan A sold $4.0M of ALAB (indirect holdings)

Dyckerhoff Stefan A sold 8,994 indirectly-held shares of Astera Labs, Inc. (ALAB) at $450.00 ($4.05M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dyckerhoff Stefan A
Published Jul 2, 2026, 11:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
high confidence
Mentioned
$ALAB
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The newest fact is the director’s $4.05M open-market sale executed July 1 under a 10b5-1 plan; the filing itself is the actionable datapoint for positioning/flow monitoring.

02

Market read

Traders may monitor insider activity for sentiment/flow, but this specific disclosure lacks new fundamentals and is likely low impact.

03

What to watch

The sale is explicitly under a pre-arranged 10b5-1 plan and is indirect holdings; without additional context (e.g., net selling trend, other filings), the signal is weak.

Relevance 5/10Novelty 5/10Timing: Filed July 2; sale executed July 1 (after-hours/next-session context).

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB).

Company-level read

Ticker impact

$ALABNeutralHigh confidence
Context

Astera Labs director Dyckerhoff Stefan A filed a Form 4 selling 8,994 shares at $450 on a 10b5-1 plan, totaling $4.05M.

Expected impact

Likely limited near-term impact; any effect should be small and transient versus broader company catalysts.

Evidence & confidence

The filing is an insider sale under a pre-arranged 10b5-1 plan, with no accompanying new operational, financial, or regulatory information in the text.

Market effects

No sector read-through is provided; the disclosure is company-specific and does not mention peers or industry developments.

None indicated; the event is an SEC Form 4 insider transaction.

None indicated; no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as reduced conviction, potentially adding mild overhang.

Key entities

  • Astera Labs, Inc.

    Subject of the Form 4 insider transaction; director Dyckerhoff Stefan A sold shares under a 10b5-1 plan.

  • Dyckerhoff Stefan A

    Director who executed the sale; reported as an open-market transaction with indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRDOMed

3 Under-the-Radar AI Stocks Wall Street Is Missing

Credo Technology (CRDO) reported Q4 2026 revenue of $437M, up 157% YoY, with guidance for 80% YoY growth in 2027. Astera Labs (ALAB) saw Q2 2026 revenue of $392.4M, up 104% YoY, with Scorpio X series ramping ahead of schedule. Camtek (CAMT) reported Q2 2026 revenue of $133.24M, up 8% YoY, with a strong order book extending into 2027.

$ALABMed

Astera Labs vs. monday.com: Comparing Revenue Trends Between These High-Growth Tech Companies

Astera Labs (ALAB) and monday.com (MNDY) both reported quarterly revenue growth. Astera Labs, which provides semiconductor-based connectivity solutions, saw revenue rise rapidly, surpassing monday.com in Q2 2026. It reported a 39% net income margin and forecasts Q3 revenue of $540M-$560M. monday.com, offering a cloud-native digital work operating system, reported a 6% operating margin and expects Q3 revenue of $368M-$370M, up 16-17% YoY. Both companies have shown consistent growth, with Astera L